Literature DB >> 24166680

Peritoneal debulking/intraperitoneal chemotherapy-non-sarcoma.

Kaitlyn J Kelly1, Garrett M Nash.   

Abstract

The combination of cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) is widely practiced for appendiceal, colorectal, gastric, and ovarian cancers with isolated peritoneal metastasis as well as for primary peritoneal cancer. The aim of this report is to explain the rationale and available techniques for CRS and IPC, and to highlight disease-specific considerations that should be taken into account when evaluating potential candidates for CRS and IPC.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  cytoreductive surgery; early postoperative intraperitoneal chemotherapy (EPIC); hyperthermic intraperitoneal chemotherapy (HIPEC)

Mesh：

Substances：

Year:  2013        PMID： 24166680     DOI： 10.1002/jso.23449

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  9 in total

1.  Recommendations in the management of epithelial appendiceal neoplasms and peritoneal dissemination from mucinous tumours (pseudomyxoma peritonei).

Authors:  P Barrios; F Losa; S Gonzalez-Moreno; A Rojo; A Gómez-Portilla; P Bretcha-Boix; I Ramos; J Torres-Melero; R Salazar; M Benavides; T Massuti; E Aranda
Journal:  Clin Transl Oncol       Date:  2015-10-21       Impact factor: 3.405

Review 2.  Abdominal metastases from colorectal cancer: intraperitoneal therapy.

Authors:  Hamza Guend; Sunil Patel; Garrett M Nash
Journal:  J Gastrointest Oncol       Date:  2015-12

3.  Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma.

Authors:  Rong Liu; Aaron H Colby; Denis Gilmore; Morgan Schulz; Jialiu Zeng; Robert F Padera; Orian Shirihai; Mark W Grinstaff; Yolonda L Colson
Journal:  Biomaterials       Date:  2016-06-23       Impact factor: 12.479

Review 4.  Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future.

Authors:  Ahmed Dehal; J Joshua Smith; Garrett M Nash
Journal:  J Gastrointest Oncol       Date:  2016-02

Review 5.  Management of Appendix Cancer.

Authors:  Kaitlyn J Kelly
Journal:  Clin Colon Rectal Surg       Date:  2015-12

6.  Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial.

Authors:  Baki Topal; Karel Demey; Halit Topal; Joris Jaekers; Eric Van Cutsem; Vincent Vandecaveye; Xavier Sagaert; Hans Prenen
Journal:  BMC Cancer       Date:  2017-11-17       Impact factor: 4.430

7.  Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study.

Authors:  Maneesh Kumarsing Beeharry; Zheng-Lun Zhu; Wen-Tao Liu; Xue-Xin Yao; Min Yan; Zheng-Gang Zhu
Journal:  BMC Cancer       Date:  2019-09-18       Impact factor: 4.430

Review 8.  [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer].

Authors:  Felix Gronau; Maximilian Jara; Linda Feldbrügge; Vincent Wolf; Alan Oeff; Beate Rau
Journal:  Chirurg       Date:  2021-02-23       Impact factor: 0.955

9.  Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients.

Authors:  Anna Weiss; Erin P Ward; Joel M Baumgartner; Andrew M Lowy; Kaitlyn J Kelly
Journal:  World J Surg Oncol       Date:  2018-04-26       Impact factor: 2.754
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.